Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) shares passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $17.76 and traded as low as $16.4250. Daiichi Sankyo shares last traded at $16.47, with a volume of 89,263 shares trading hands.
Analyst Ratings Changes
A number of equities analysts recently weighed in on DSNKY shares. Zacks Research lowered shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. Jefferies Financial Group downgraded Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce”.
Read Our Latest Research Report on DSNKY
Daiichi Sankyo Stock Down 7.9%
The business has a 50-day moving average of $17.81 and a 200-day moving average of $17.76.
Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last released its earnings results on Friday, July 31st. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. Research analysts expect that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.93 EPS for the current year.
Daiichi Sankyo Company Profile
Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.
Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.
Further Reading
- Five stocks we like better than Daiichi Sankyo
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
